1. Home
  2. HQI vs IKT Comparison

HQI vs IKT Comparison

Compare HQI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

N/A

Current Price

$16.10

Market Cap

232.1M

ML Signal

N/A

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.49

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HQI
IKT
Founded
2002
2008
Country
United States
United States
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.1M
220.5M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
HQI
IKT
Price
$16.10
$2.49
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$13.00
$5.00
AVG Volume (30 Days)
23.6K
391.2K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
2.08%
N/A
EPS Growth
73.08
57.76
EPS
0.31
N/A
Revenue
$30,640,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.46
N/A
P/E Ratio
$53.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.38
$1.33
52 Week High
$19.01
$2.61

Technical Indicators

Market Signals
Indicator
HQI
IKT
Relative Strength Index (RSI) 55.82 58.17
Support Level $12.14 $2.31
Resistance Level $17.78 $2.53
Average True Range (ATR) 0.99 0.11
MACD -0.17 -0.01
Stochastic Oscillator 58.10 63.24

Price Performance

Historical Comparison
HQI
IKT

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: